Elsevier

The Lancet Oncology

Volume 17, Issue 9, September 2016, Pages 1189-1190
The Lancet Oncology

Comment
Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment

https://doi.org/10.1016/S1470-2045(16)30283-2Get rights and content

References (9)

There are more references available in the full text version of this article.

Cited by (2)

  • The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)

    2017, The Lancet
    Citation Excerpt :

    Second, the traditional methods used to characterise long-term morbidity in survivor populations, such as cumulative incidence and prevalence of health conditions,6–8,21 only describe the first occurrence of an outcome and do not adequately show the many different morbidities that occur in the survivorship population. By analysing the cumulative burden (a method of disease burden measurement that incorporates multiple health conditions and recurrent events into a single metric) in the SJLIFE cohort, we define the landscape of disease burden by providing a clinically informative description of the long-term pattern of morbidity in survivors of childhood cancer.12,22 Using cumulative prevalence, we previously reported that by age 45 years, 95·2% of survivors in the SJLIFE cohort had at least one CHC and 80% had at least one serious, disabling, or life-threatening CHC.5

View full text